CANCER DISCOVERY

CONTENTS

JANUARY 2012 ■ VOLUME 2 ■ NUMBER 1















RESEARCH ARTICLES

For more News and Research Watch, visit *Cancer Discovery* online at www.AACR.org/CDnews. Online-only News stories include the following:

- Biotech Firms Look for Virtual Success
- "Reversed" Krebs Cycle Can Feed Tumors
- Dual HER2 Blockade Slows Metastatic Breast Cancer
- Modified Stem Cells Create Tumor-Attacking T Cells

ON THE COVER

Wagle and colleagues describe a method to profile clinically relevant mutations in formalin-fixed, paraffin-embedded tumor samples involving exon capture of frequently mutated or polymorphic genes followed by massively parallel sequencing. This method identifies single-nucleotide variants, insertions, deletions, and copy number alterations overlooked by current genotyping-based methods with high specificity and sensitivity. Identification of such "actionable" genetic alterations that predict response to targeted or conventional cytotoxic therapies has the potential to facilitate individualized cancer treatment in a time- and cost-effective manner. For details, please see the article by Wagle and colleagues on page 82.

AACR American Association for Cancer Research

CANCER DISCOVERY

2 (1)

Cancer Discovery 2012;2:vi-93.